Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00587054 · ClinicalTrials.gov registry record · Phase 2
Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
NCT00587054: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00587054 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 129 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00587054, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
Study Summary
This is a phase II, single-center study to evaluate the efficacy of a novel cytoreductive regimen followed by CD34+E- selected T cell depleted allogeneic stem cell (or soybean agglutinated and E-rosetted BM) transplant as treatment for patients with acute and chronic leukemias, lymphoma and myelodysplstic syndrome/PNH. The impact of the change in conditioning regimen and use of CD34-selected T cell depleted PBSCs on transplanted related morbidity and mortality and disease free survival will be assessed.
Interventions
- DRUG cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2001-06 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00587054
The ClinicalTrials.gov registry entry for NCT00587054 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant is the first listed.
NCT00587054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00587054 about?
NCT00587054 is a clinical study titled "Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders". This is a phase II, single-center study to evaluate the efficacy of a novel cytoreductive regimen followed by CD34+E- selected T cell depleted allogeneic stem cell (or soybean agglutinated and E-rosetted BM) transplant as treatment for patients with acute and chronic leukemias, lymphoma and myelodys...
What is the current status of trial NCT00587054?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2001-06. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00587054?
The interventions under investigation include: cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant (DRUG).
Who is sponsoring clinical trial NCT00587054?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.